Clinical guide · NAD+ dose
A practical comparison of Clinic Terrain’s four current NAD+ IV levels and the clinical inputs used to choose between them.
For people comparing NAD+ IV doses, expected time, first-session tolerance and physician clearance in Bali.See the physician-led NAD+ pathway →
The lowest current protocol creates a bounded starting point when the physician considers it appropriate. It can provide practical information about administration and individual tolerance without assuming that a larger number is the correct first choice.
This intermediate route sits between entry exposure and the higher-dose protocols. Prior response, current condition, objective, medication and the time available remain part of the decision.
A 500mg protocol represents a materially larger administration than the entry route. Expected duration, supervision, tolerance and the reason for selecting it should be explicit before booking.
Clinic Terrain requires physician clearance and a dedicated 4–6 hour window for the 750mg protocol. It is a distinct clinical and operational commitment, not a menu upgrade.
Dose, duration, rate changes, symptoms and the patient’s report are captured in the living record. A repeat decision can then use observed tolerance rather than starting again from a generic menu.
Connected clinical library
Dose, duration, cost, evidence, tolerance and the clinical checks that connect them.
Direct answers
There is no universal website rule. The physician selects the route from the relevant clinical context, prior exposure, objective and operational setting.
No. Dose size alone does not guarantee a particular clinical or subjective result. Suitability and response remain individual.
It is the largest current protocol and Clinic Terrain reserves a 4–6 hour window so administration and tolerance can be managed under physician clearance.
Evidence position
Sources used for this page
Human studyGrant et al.: intravenous NAD+ metabolome pilot (2019) ↗Direct six-hour IV NAD+ administration and measured metabolic changes; a small pilot, not proof of broad clinical benefit.Human studyReal-world IV NAD+ and IV NR tolerability pilot (2026) ↗Exploratory infusion duration, symptoms and short-term biomarkers; retrospective data, not an efficacy trial.Scientific reviewVerdin: NAD+ in ageing, metabolism and neurodegeneration (2015) ↗Established NAD+ biology and mechanistic context; it does not establish outcomes from IV therapy.Your first message · Where you are + what you need help with